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1. Introduction
1.1. Menopause: endocrinology and symptoms
Menopause is a physiologic process in women that occurs around 45-55 years old, which is
defined as permanent cessation of menstruation by one year in row [1]. The age of meno‐
pause depends on multiple factors such as number of ovules from the female at birth, the
frequency of loss of these ovules through her life and the number of ovarian follicles re‐
quired maintaining the menstrual cycle. The diagnosis of menopause is retrospective and is
established after a year without menses [2], and their symptoms may have different intensi‐
ty for each woman [3].
This process is characterized by gradual decrease of estrogen (E) secretion and changes re‐
lated with sex hormones, so that estradiol levels ranging from 5 to 25 pg/mL, while increas‐
ing titers of gonadotrophins, so that the values of follicle stimulating hormone (FSH)
between 40 and 250 mU/mL and luteinizing hormone (LH), from 30 to 150 mU/Ml [4, 5].
Irregular uterine bleeding is a characteristic symptom which is due to both depletion and
resistance of ovarian receptors to gonadotropins and increased FSH, leading to alterations in
the volume and frequency of bleeding (polymenorrhea, hypo-or menorrhagia, oligomenor‐
rhea) [6, 7].
Among symptoms are those related to the genitourinary tract by the common embryological
origin of vulva, vagina, bladder, and urethra, consequently alterations as dysuria, urinary
urgency and incontinence, epithelial atrophy, decreased production of mucus and vaginal
dryness (phenomena that can cause dyspareunia), urethritis, vaginitis or cystitis and local
infections [8, 9, 10] (Figure 1).
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Figure 1. Main genitourinary abnormalities according to age in women [10].
Figure 2. Changes observed in muscle mass and strength after menopause [16].
Hot flushes are one of the main symptoms associated with menopause and occur in more
than 75% of menopausal, consisting of intense episodes of heat that begins on chest and
spreads to face, sweating, and flushing of face. Hot flushes are associated with headache,
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anxiety and palpitations, and it usually lasts 2-4 minutes and can vary in frequency, in some
women may be daily while others may have one episode per month [11, 12]. The mechanism
of hot flushes is not clear, however, it is known that hypothalamus, pituitary gonadotropin
releasing hormone and gonadotrophins may be involved in hot flushes [13]. Another fre‐
quent symptom is an oral dryness and intense burning sensation that affects mainly the
tongue and sometimes lips and gums [14].
On the other hand decreases the content of collagen and elastic fibers of the skin, so that it
becomes thinner and brittle losing elasticity and firmness. The epidermis thins, increases
water loss and reduces the number of blood vessels, compromising the supply of oxygen
and nutrients [15]. Additionally aging is associated with a natural decline in physiological
functions, including a loss of muscle mass and strength. Overall, the decline in muscle mass
averages 0.4 to 0.8 kg per decade, starting at the age of 20 years, especially around meno‐
pause [16] (Figure 2).
Another alteration that occurs is the osteoporosis, which is defined as a skeletal disorder
characterized by decreased bone density and an increased risk of fractures [17, 18]. Before
reports have confirmed that postmenopausal women have highest incidence of hip fractures
[19, 20, 21] (Figure 3).
Figure 3. Bone mineral density values by age in women. Bone mineral density decreases around menopause [21].
Menopause is a stage that favors weight gain and development or worsening of obesity,
and causes of this problem are many; some are clearly related to hypoestrogenism and oth‐
er age-dependent, conditioning increased intake and decreased energy expenditure [22, 23]
(Figure 4).
During this period there is an abnormal atherogenic lipid profile characterized by increased
lipoprotein cholesterol, low density (LDL-C), triglycerides (TG) and small dense LDL parti‐
cles [24] with reduced HDL-C and elevated serum glucose and insulin, perhaps as a direct
result of ovarian failure or indirectly as a result of central redistribution of body fat, and this
favors the formation of atheromatous plaques and progression of coronary atherosclerosis
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and therefore cardiovascular disease incidence increases substantially in postmenopausal
women [25, 26]. Other disorders such as obesity and metabolic syndrome also occurs at
menopause, suggesting that menopause may be the trigger of the metabolic syndrome at
that stage of life [27, 28].
Figure 4. Body fat distribution. Android-type distribution is present in postmenopausal women. DXA= Dual-energy X-
ray absorptiometry [23].
Postmenopausal women have higher insulin resistance than premenopausal, which could
participate to age, the increase in total body fat, central adiposity, estrogen deficiency, alter‐
ations in lipid profile and glucose homeostasis and insulin are more frequent and favor the
high cardiovascular morbidity and mortality after menopause. In this sense the transition of
menopause is marked by changes in hormonal balance, with increased visceral fat, which
are associated with insulin resistance, although it has been found that the change in insulin
sensitivity does not alter the lipid profile in early postmenopausal women [24, 26] (Figure 5).
Figure 5. Changes lipid during transition from premenopause to Postmenopause [24].
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Depression occurs frequently in postmenopausal women, which is explained by the loss of
estrogenic effect in modulating neuronal excitability, synaptic plasticity, neuronal survival
induced expression of regenerative responses, regional neurogenesis, regulation of differen‐
tiation and neuronal development [29], in the processes of cognition, modulation of mood
and other mental states, as well as improving learning and memory [30], regulate the syn‐
thesis of tryptophan hydroxylase which is the limiting enzyme in serotonin synthesis so this
decline in estrogen at menopause may explain the occurrence of psychological symptoms
characteristic of depression (fatigue, irritability, sleep problems, abrupt changes of mood,
[31]. With respect depressive symptoms in the Multiethnic Study of Atherosclerosis were
analyzed testosterone, estradiol, steroid hormone binding globulin (SHBG) and dehydroe‐
piandrosterone; indicating that in early postmenopausal women, sex hormones were associ‐
ated with incident depressive symptoms [32].
2. Pro and antioxidants propierties of estrogens
Throughout menopause there are factors that predispose women to the development of oxi‐
dative stress, such as estrogen deficiency, as it has been confirmed that they have an antioxi‐
dant capacity independently of its binding to receptors, so for example the 17β-estradiol
(E2), estriol, estrone, ethinylestradiol and 2-hidroxiestradiol besides reducing neuronal
death with antioxidant activity, due to the presence of an intact hydroxyl group on ring A of
the molecule [33].
Estrogens are synthesized from different androgen precursors such as androstenedione and
testosterone, yielding as products estrone and 17β-estradiol, respectively. The synthesis is
catalyzed by aromatase (ARO), the enzyme cytochrome P450 (CYP19) and estrogen synthe‐
sizing different tissue-specific manner, and the major estrogen in adipose tissue is estrone,
the placenta is estriol and in cells granulosa is 17β-estradiol [34].
The 2-hidroxiestradiol and 2-hydroxyestrone (4-hidroxiestradiol type) (Figure 6) can partici‐
pate in redox cycling to generate free radicals such as superoxide and chemically reactive es‐
trogen semiquinone/quinone, which can damage DNA and other intracellular constituents.
4-hidroxiestradiol participates in a redox cycle to generate free radicals such as superoxide,
and intermediate semiquinone/quinone, these intermediaries may induce cell transforma‐
tion and initiate tumoral growth [35].
4 - hydroxyestrogens have estrogenic effects and can stimulate the growth of cell lines of
breast cancer, with greater intensity than the 4-hydroxyestrone are unstable and can become
highly reactive quinone with the formation of semiquinones as intermediary, this reaction
produces oxygen free radicals, which can have toxic effects on DNA, such effects include the
formation of 8-hydroxy-2-deoxiguanosine a mutagen, resulting from oxidative damage. The
toxic effect of 4-hydroxyestrogens probably is prevented under normal conditions intracel‐
lular defense mechanisms. Oxygen free radicals can be removed immediately transformed
into water by enzymes such as catalase and superoxide dismutase and antioxidant vitamins
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such as ascorbic acid and alpha tocopherol, quinone themselves can be inactivated by sulfo
compounds, such as glutathione [36].
Figure 6. Estrogen metabolism.
Menopause seems to accelerate the development of atherosclerosis and cardiovascular dis‐
eases and in order to identify this correlation, was assessed the correlations between intima-
media thickness, homocysteine serum levels and oxidative stress both in fertile and
postmenopausal women and it was founded that were increased levels of homocysteine, ox‐
idative stress and intima-media tickness (IMT) in postmenopausal women having a positive
correlation with IMT, which reinforce the idea that a hyperhomocysteinemia may play a role
in the progression of atherosclerosisas a result the lack of estrogens [37].
Vasculo protective effects of estrogen are due in part to the modulation of the balance be‐
tween nitric oxide (mainly derived from endothelial vasodilator molecule) [38] and superox‐
ide anion (oxygen-free radical highly reactive), promoting the availability of the first such so
the lack of protection induces high levels of oxidative stress and low concentrations of NO,
these processes are interacting with hypertension, as seen in menopause. In addition, estro‐
gen induces the expression of oxide reductasesthiol / disulfide, such as disulfide isomerase,
thioredoxin, thioredoxinreductase and glutaredoxin in the endothelium and inhibits apopto‐
sis mediated by hydrogen peroxide. On the other hand has been described that genetic fac‐
tors related to dyslipidemia are most important than due to age, for example antioxidant
enzymes (SOD, catalase, GR, inflammatory markers CPR, ALT), oxidative stress (O(2)(-),
LOO•), hypoxia (HBNO) and all this related to increase vascular resistance, disorders in
oxygen supply in tissue and hypoxic competitions of there metabolism may cause, postme‐
nopausal hypertension, hart ischemic disease, impaired hepatic beta-oxidation of fatty acids
and hepathosteatosis [39].
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17-β-estradiol plays a critical role in neuroprotection through both genomic and non-genom‐
ic mechanisms and recently was discovered that a new G-protein-coupled receptor 30
(GPR30) participates in the neuroprotection against oxidative insult, which is agonist G1. E2
attenuated apoptosis induced by H2O2 exposure, furthermore, G1 or E2 significantly in‐
creased the levels of phosphorylated extracellular signal-regulated kinase 1/2 (p-ERK1/2),
Bcl-2 and pro-caspase-3, which is an anti-apoptotic effect [40].
3. Oxidative stress and postmenopause
Actually several oxidative stress biomarkers have been studied in menopause, however,
each researcher has used different marker, methodologies and women with dissimilar char‐
acteristics (age, ethnic group, postmenopause time), fact does difficult to make a conclusion
about the development of oxidative stress during peri, menopause and postmenopause.
Recently has been propose as indicator to γ-glutamyltransferase (GGT) which is an enzyme
involved in the transfer of the γ-glutamyl residue from γ-glutamyl peptides to amino acids,
H2O, and other small peptides and can be donated by glutathione [41]. On the other hand,
GGT is also involved in the production of glutathione [42], which is limited by cysteine
availability. GGT participates in the pathway of extracellular GSH in consequence the bio‐
synthesis of cellular glutathione, the most important cell antioxidant, depends of GGT activ‐
ity; hence this enzyme may play an important role in the anti-oxidative defense system of
the cell [43].
Abdul et al, founded a highly significant reduction in glutathione levels in the post-menopaus‐
al-group which could be due to the increase in its free radical scavenging property and in‐
creased  consumption  to  counteract  the  oxidative  stress  and  to  inhibit  membrane  lipid
peroxidation which indicates that the increase in serum GGT with enhanced oxidative stress
and reduced antioxidant defense system in the post-menopausal women may lead to the spec‐
ulation that GGT could be considered an index or a oxidative stress marker [43] (Table 1).
Serum level Premenopausal
Group (n=17)
Postmenopausal
Group (n=16)
p value
GGT (U/L) 5.96±2.99 9.44±2.89 0.025
GSH (mmole/L) 0.62±0.17 0.47±0.11 0.008
MDA (µmole/L) 1.04±0.06 1.32±0.05 0.035
Table 1. Serum γ-glutamyltransferase, glutathione and malondialdehyde levels in the pre- and postmenopausal
women [43].
Supplementary it was found that perimenopausal women have higher total cholesterol val‐
ues and lower paraoxonase-1 (PON1) activity compared to reference values, 8-oxoG levels
were unchanged compared with those of healthy control women, lipoperoxide ranks were
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significantly increased compared with those of premenopausal women and an indirect cor‐
relation between PON1 arylesterase (PON1 A) activity and lipoperoxide levels, between
PON1 A activity and atherogenic index, between age and TAS, and between age and 8-oxoG
levels. Moreover perimenopausal women had higher total cholesterol levels and PON1 A
levels were lower than physiological values (table 2) [44].
Variable Average±SD or median Physiological values
TCH 5.673±0.856 mmol/L ฀5.17 mmol/L
TG 1.424±0.66 mmol/L ฀1.9 mmol/L
LDL 3.103±0.649 mmol/L ฀3.5 mmol/L
HDL 1.563±0.445 mmol/L ฀1.4 mmol/L
Atherogenic index
(TCH/HDL)
3.853±1.009 ฀5.2
PON1 A 89.628±14.798 U/mL 100-200 U/mL
Pon1 L 12.213±2.956 U/mL 13-20 U/mL
Homocysteine 8.48±2.97 µmol/L ฀12 µmol/L
Glycemia 5.43µ0.65 mmol/L 4.2-6.2 mmol/L
Uric acid 246.5 (209.9-296.9) µmol/L ฀339µmol/L
Table 2. Data showing departures from normality are expressed as median values with the respective lower and
upper quartile. The boldfaced entries indicate values beyond the reference range. PON1 A, paraoxonase with
arylesterase activity; PON1 L, paroxonase-1 with lactonase activity.Paroxonase-1 levels in perimenonausal women [44].
Another finding is the lipoperoxide level which was significantly increased in perimeno‐
pausal women (Table 3). The levels of the marker of oxidative damage to DNA-8-oxoG were
not statistically between pre and perimenopausal. In contrast women in perimenopause had
repair ability 4 times higher compared with premenopausal women and significantly in‐
creased plasma total antioxidant capacity (TAS) [44] (Table 3).
Variable Perimenopausal women Controls (premenopausal)
TAS 1.532±0.095 mmol/La 1.230±0.100 mmol/mL
Lipoperoxides 37.995 (32.035-44.849) nMol/mLa 28.096 (23.103-30.850) nmol/mL
8-oxoG 0.464 (0.283-0.957) per 106 G 0.503 (0.337-0.674) per 106 G
Repair ability 36.919% (30.679%-47.046%)a 10.539% (8.665%-11.475%)
Table 3. Data showing departures from normality are given as median values with the respective lower and upper
quartile. athese values are significantly different (P฀0.005) compared with controls. Profile oxidant and antioxidant
between premenopausal and perimenopausal women [44].
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In another study were determined age, body weight, and superoxide dismutase (SOD), cata‐
lase (CAT) and malondialdehyde (MDA) in disease-free women aged 25-65 years and did
found that postmenopausal women had the highest oxidative stress and body weight, also
superoxide dismutase, catalase and malondialdehyde were correlated significantly with
body weight [45].
Pansini demonstrated that the total body fat mass increases significantly in postmenopause
in comparison with premenopause, with specific increases in fat deposition at the level of
trunk (abdominal and visceral) and arms. Concomitantly, the antioxidant status adjusted for
age showed that antioxidant status was retained. Also both antioxidant status and hydro‐
peroxide level increased with trunk fat mass [46].
Also has been carried out protocols that analyze the connection between menopause and pe‐
riodontal conditions, though to compare serum and gingival crevicular fluid (GCF) total an‐
tioxidant capacity (TAOC) and superoxide dismutase (SOD) concentrations in post-
menopausal patients with chronic periodontitis (PMCP) with those of pre-menopausal
chronic periodontitis patients (CP). The results showed Serum and GCF TAOC and SOD
concentrations were significantly lower in menopause and periodontitis, the lowest values
were in the PMCP group, whereas the highest values were in premenopausal. While the ef‐
fect of menopause was more evident in serum antioxidant analysis, the consequence of pe‐
riodontitis was observed to be more apparent in GCF and a decrease in systemic and local
AO defense was observed owing to both menopause and periodontitis [47].
Risk factor OR 95% CI Pa
Menopause (hypoestrogenism) 2.62 1.35-5.11 0.005
Consumption of alcoholic beverages (≥2 glasses/d) 2.49 0.28-22.50 0.417
Smoking (≥2 cigarettes/d) 1.98 0.58-6.82 0.277
Overweight (฀25 kg/m2) 1.43 0.64-3.18 0.383
Insomnia (AIS score ≥8) 1.13 0.58-2.22 0.715
Age, y 1.04 0.94-1.14 0.466
Physical inactivity (฀30 min/d of physical activity) 0.85 0.43-1.68 0.632
Table 4. OR, odds ratio; AIS, Athens Insomnia Scale.aLogistic regression, R2=0.106, P=0.036.Risk factors for high
lipoperoxide levels, as oxidative stress biomarker, in perimenopausal women [49].
Unsaturated fatty acids have a role in the pathogenesis of atherosclerosis. They are very sen‐
sitive to oxidation caused by excess free oxygen radicals and the consequent oxidative sta‐
tus, and it is well known that lipid and lipoprotein metabolism is markedly altered in
postmenopausal women as it was demonstrated by Signorelli who founded that the oxida‐
tive stress is involved in the pathophysiology of atherosclerosis. Malonaldehyde (MDA), 4-
hydroxynenal (4-HNE), oxidized lipoproteins (ox LDL) were higher in postmenopausal
while GSH-PX concentrations were significantly higher in fertile women [48].
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Similar findings were found in pre and postmenopausal Mexican women by Sánchez. Lipo‐
peroxides, erythrocyte superoxide dismutase and glutathione peroxidase activities, the total
antioxidant status, pro-oxidant factors, body mass index were evaluated. The lipoperoxide
levels were significantly higher in the postmenopausal group than in the premenopausal
group, which concluded that menopause is the main risk factor for oxidative stress [49].
However, there are other contrasting studies, in example in a report was found than postme‐
nopausal women had lower levels of lipid hydroperoxide oxidation, the MDA levels did not
differ between pre- and postmenopausal women, no differences in advanced oxidation pro‐
tein products (AOPP) and nitrite levels were observed between pre- and postmenopausal
women. Postmenopausal women also exhibited a higher total radical antioxidant level [50].
Another study included pre-menopausal, peri-menopausal, and post-menopausal women
classified according to the Staging of Reproductive Aging Workshop (STRAW) criteria. No
significant correlations between E2 levels and OS markers were detected and consequently,
estrogen decline during menopausal transition is not a determinant factor for oxidative
stress [51].
4. Associated diseases to oxidative stress
There are several evidences that related to oxidative stress with diseases present in postme‐
nopausal women in example depression, osteoporosis, cardiovascular diseases and leg vaso‐
constriction.
DEPRESSION
The depression is the most frequent symptom in postmenopausal women, even is a major
cause of medical consultation. This disorder has cerebral implications, as showed post-mor‐
tem studies in patients with depressive disorder pointed a significant decrease of neuronal
and glial cells in cortico-limbic regions which can be seen as a consequence of alterations in
neuronal plasticity. This could be triggered by an increase of free radicals which in its turn
eventually leads to cell death and consequently atrophy of vulnerable neuronal and glial cell
population in these regions [52]. In addition elevated levels of MDA adversely affected the
efficiency of visual-spatial and auditory-verbal working memories; short-term declarative
memory and the delayed recall declarative memory were founded. 1. Higher concentration
of plasma MDA in recurrent depressive disorder (rDD) patients is associated with the se‐
verity of depressive symptoms 2. Elevated levels of plasma MDA are related to the impair‐
ment of visual-spatial and auditory-verbal working memory and short-term and delayed
declarative memory [53]. Actually too is known that estrogen protect neurons against oxida‐
tive damage excitotoxins, and beta-amyloid-induced toxicity in cell culture, reduces the se‐
rum monoamino oxidase levels and might regulate learning and memory. Nitric oxide (NO)
is a messenger and in the central nervous system and acts as neurotransmitter/neuromodu‐
lator like serotonin, bradykinin, endothelin, acetylcholine and noradrenaline. Estrogen indu‐
ces activity of constitutive NO synthase, reduces hyperphosphorylated of Tau and
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stimulates phosphorylated GSK3b [54]; due to in menopause its reduction induces a depres‐
sive disorder [55].
OSTEOPOROSIS
Oxidative stress participates in decreasing bone formation and stimulating bone resorption.
Furthermore, antioxidant enzymes have been observed to have low protective activity in
women with osteoporosis, also has been determined higher urine deoxypyridinoline, total
Peroxide (TPx), MDA, nitric oxide, also lower TAS and glutathione reductase, compared
with postmenopausal women whitout osteoporosis [56, 57]. Likewise has been studied poly‐
morphism associated with enzymes involved in oxidative balance such as of the glutathione
S-reductase (GSR), superoxide dismutase (SOD1 and SOD2), and catalase (CAT), of which
polymorphisms from GSR were associated to bone mineral density [58]. Both oxidative
stress and associated polymorphisms are useful tool to predict which patients might devel‐
op osteoporosis.
CARDIOVASCULAR DISEASES
Oxidative stress biomarkers have been linked with the presence and severity of the CVD,
and to the presence and number of risk factors. It is known that young women during their
fertile life are at lower risk of cardiovascular events compared with men, being protected by
estrogen action and that oxidative stress is generally higher in men than in premenopausal
women. However, after menopause the risk of experiencing cardiovascular events rapidly
rises in women, in conjunction with a parallel increase in oxidative stress. Moreover, al‐
though oxidative stress results are lower in females compared to males during the first deca‐
des of life, this difference decreases until the age range which corresponds to the onset of
menopause for women [59].
An analyses of relationship among excess iron, oxidative stress, and centralized fat mass in
healthy postmenopausal women showed that almost 14% of the variability in oxLDL was
accounted for by centralized fat mass AndGynFM ratio (waistþhip=thigh¼AndGynFM),
age, and serum iron. Similarly, 16% the variability in 15-isoprostane F2aα (PGF F2aα) was ac‐
counted for by the AndGynFM ratio, HOMA, and serum iron. Also it was accounted for
33% of the variability in AndGynFM ratio by high-density lipoprotein cholesterol (HDL-C),
ferritin, HOMA, oxLDL, and PGF F2aα, all of before suggests that reducing centralized fat
mass and maintaining a favorable lipid profile, antioxidant status, and iron status all may be
important in protecting postmenopausal women from atherosclerotic CVD [60]. Similar
findings has been observed in diabetic postmenopausal women in whom it has been report‐
ed higher levels of total cholesterol (TC), triglyceride (TG), low density lipoprotein choles‐
terol (LDL-C), very low density lipoprotein cholesterol (VLDL-C), catalase (CAT), and
malondialdehyde (MDA) and significantly lower levels of HDL-C, reduced glutathione
(GSH), glutathione reductase (GR), glutathione peroxidase (GPx), and superoxide dismutase
(SOD) [61]. Fact means a cardiovascular risk.
LEG VASOCONSTRICTION
Leg vasoconstriction has been linked to oxidative stress due to the fact that Intravenous ad‐
ministration of a supraphysiological dose of the antioxidant ascorbic acid increased leg
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blood flow in the postmenopausal women as a result of an increase in leg vascular conduc‐
tance, but it did not affect leg blood flow in premenopausal controls or mean arterial pres‐
sure, also changes in leg blood flow and leg vascular conductance with ascorbic acid were
related to high plasma oxidized LDL an low antioxidant status [62] (Table 5, Figure 7).
Variable Premenopausal Postmenopausal
Oxidized LDL, U/l 36.9±4.9 55.6±3.3*
TAS, mmol/l 1.4±0.1 1.1±0.1*
ACE, U/l 26.2±3.9 30.3±2.6
Endothelin-1, pg/ml 4.8±0.5 5.3±0.3
Norepinephrine, pg/ml 149±39 343±28*
Epinephrine, pg/ml 20±3 27±2
Table 5. Values are means ±SE, ACE angiotensin-converting enzyme. *P฀0.05 vs premenopausal.Serum biomarkers
associated to leg vasoconstriction [62].
Figure 7. Relationship between plasma oxidized low-density lipoprotein (LDL) and the change in femoral artery BF
(top) and vascular conductance VC (bottom) with ascorbic acid in premenopusal ( ฀) and postmenopausal (●) women
[62].
In addition, long-term studies indicate that total cholesterol (TC), LDL cholesterol (LDL-C),
triglycerides (TG), MDA and common carotid artery wall intima-media thickness (IMT) are
higher in women with hormonal depletion over 5 years, reveling a close temporal correla‐
tion between plasma oxidative and carotid wall IMT as postmenopause proceeds [63].
Further investigations are needed to examine the roll of oxidative stress as an endogenous
bioactive agent related to disease in post-menopausal women. Since oxidative stress is the
imbalance between total oxidants and antioxidants in the body, any single oxidant/ antioxi‐
dant parameter may not reflect oxidative stress. Further studies are needed to understand
the underlying mechanisms of before findings.
5. Hormonal replacement therapy
Hormone replacement therapy (HRT) is defined as treatment that estrogen provides women
to improve the characteristic symptoms of menopause [64], especially osteoporosis, dyslipi‐
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demias, mood among others, is also important to note that hormone replacement therapy is
not without risks.
There are three Hormonal Replacement Therapies (HRT) treatment regimens:
• 1.- Estrogens. They may be natural or synthetic. Estrogens (17β-Estradiol and Estriol) and
conjugated equine estrogens, and these are administered orally. Estrogens may adminis‐
trated by oral, subcutaneous routes, also intravaginal estrogen (tablets, creams, ovules),
alone or combined with progestin, are suitable for vaginal symptoms, with no significant
increase in endometrial hyperplasia or proliferation.
• 2 - Progestogens. They are administered in combination with estrogen to reduce the risk
of endometrial hyperplasia and cancer. Currently most used active ingredients TH are:
oral micronized progesterone, medroxyprogesterone and norethisterone. Progestins are
mainly used orally, although there are preparations to be administered in combination
with estrogen transdermal route [65].
• 3 - Another group of drugs called STEAR (Selective Tissue Estrogenic Activity Regulator)
is widely used because it has tissue-specific metabolism, and a main representative is Ti‐
bolone, this is a synthetic steroid with weak estrogenic, androgenic and gestagenic activi‐
ties, which controls vasomotor symptoms, prevents bone demineralization and improves
mood [66]. Tibolone improves vaginal symptoms and no significant differences when
compared to estrogen, decreases menopausal symptoms, although moderately increases
bone density and inhibit bone resorption. In the cardiovascular system there is no evi‐
dence of efficacy for the primary or secondary prevention of diseases associated with
menopause at this level [67].
6. Effects of hormonal replacement therapy on oxidative stress
As mentioned above, there are different pathologies in the menopause that improve after ad‐
ministrating of hormone replacement therapy, fact that aroused the interest in evaluating their
effects on biomarkers of oxidative stress, which has been recognized its participation in illness‐
es as cancer, atherogenesis, Alzheimer's and aging among others. Below are described the find‐
ings on changes in oxidative stress biomarkers after administrating HRT by periods time.
LESS THAN THREE MONTHS
In African American and Caucasian posmenopausal women the HRT reduced plasma levels
of free 8-isoprostane after 6 weeks of HT, at the same time nitrite increased, principally in
Caucasian women. Both ethnics groups have reduced levels of oxidative stress but the dif‐
ferences were not statistically significant [68]. Even the combined therapy for 3 months had
an antioxidant effect in posmenopausal hemodialysis women, who showed reduced levels
of MDA although TAC, uric acid and C- reactive protein were not changed [69].
Oxidized low-density lipoprotein (oxLDL)/β2-glycoprotein I (β2GPI) complexes are etiologi‐
cally important in the development of atherosclerosis. Combined HRT led to a significant
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increase in TAC and a minor but statistically nonsignificant decrease of oxLDL/β2GPI com‐
plexes when compared with the baseline control levels. There was also no significant associ‐
ation between TAC and oxLDL/β2GPI complexes changes related to HRT. This study
indicates that, HRT in postmenopausal women leads to an increase in TAC without an
equivalent change in serum levels of oxLDL/β2GPI complexes. It is concluded that beneficial
effects of HRT could be explained, at least in part, by improving antioxidant status, but may
not be directly associated with a change in oxidized lipoprotein production [70] (Figure 8).
Figure 8. Effects of hormone replacement therapy (HRT) on oxLDL/β2GPI (a), total antioxidant capacity (TAC) (b),
oxLDL/β2GPI to HDL-C ratio (c) in the studied subjects. Values are means ± SE. P < 0.05 (paired sample t-test). total
serum antioxidant capacity (TAC) as ferric reducing ability of plasma (FRAP) and related these to HRT and oxLDL/β2GPI
complexes level [70].
SIX MONTHS
The main studies about effect of HRT has been carried out with combination estrogen plus
gestagen, and in them has been founded in example that carbonils groups determined by
ELISA showed a reduction of serum levels after six months oral or transdermal treat when
compared with control group, and there was not difference between oral and transdermal,
which indicates that hormonal therapy reduces the of carbonyl protein, a marker of oxida‐
tive stress, suggesting potential protective effect [71]. Similar result were founded with the
serum level of malondialdehyde, superoxide dismutase and sulfhydryl groups without
changes on plasma total homocysteine (tHcy) (used as atherogenic indicator) [72]. Another
study with equal number of months of follow-up showed that carbonyls, MDA and oxLDL
were reduced, while erythrocyte glutathione (GSH) were increased, and nitrotyrosine (NT)
levels were not changed [73, 74] (Table 6).
On the other hand Tibolone treatment leads to a decrease in concentrations of plasma lipid
peroxide, increase plasma concentrations of vitamin E and alpha-tocopherol and significant
decrease in lipid peroxide concentrations [75, 76].
ONE YEAR
However, the combined treatment by one year significantly reduced the levels of catechola‐
mines, mean blood pressure and LDL cholesterol while it increased levels of nitrite/nitrate,
indicating cardiovascular benefit in healthy recent postmenopausal women. Levels of 8-epi
PGF2alpha did not change, suggesting no evident relationship between HRT and oxidative
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stress [77]. Although another study reports that conjugated estrogens alone (EHRT) or con‐
jugated estrogen with medroxyprogesterone acetate can reduce lipoprotein lipase (LPL),
hepatic lipase (HL), oxidized apolipoprotein B in LDL [78] also platelet MDA, glutathione-S-
transferase (GST) and SOD levels were lower and total thiol (t-SH) content was higher than
pre-treatment levels. These results indicate that hormone replacement therapy may affect
platelet membrane fatty acid content and oxidant-antioxidant balance in postmenopausal
women [79].
MPA n=25 NETA n=20 Total n=45
Total-C
Pre/postreatment (mg/100ml)
204.1±30.0/
178.6±10.7*
225.7±30.1/
191.6±21.1*
213.7±31.7/
184.4±17.2*
HDL-C
Pre/postreatment (mg/100ml)
45.7±10.6/
53.2±7.6*
49.1±11.0/
56.6±8.2
47.2±10.8/
54.8±8.0*
LDL-C
Pre/postreatment (mg/100ml)
131.7±24.9/
102.8±13.6*
147.5±25.2/
112.7±21.2*
138.71±26.08/
107.2±17.9*
Triglycerides
Pre/postreatment (mg/100ml)
133.5±62.0/
115.2±35.2
138.4±74.4/
113.5±37.0
135.67±67.1/
114.4±35.6
MDA
Pre/postreatment (mg/100ml)
4.7±0.4/
4.0±0.4*
4.9±0.4/
3.6±0.3*
4.82±0.4/
3.8±0.4*
OxLDL
Pre/postreatment (mg/100ml)
54.9±8.5/
47.9±4.0*
53.1±8.3/
44.8±4.4*
54.13±8.34/
46.6±4.4*
PON 1
Pre/postreatment (mg/100ml)
51.5±6.7/
73.9±11.2*
51.4±9.0/
67.4±10,0*
51.47±7.7/
71.0±11.1*
Table 6. Comparinson of parameters before and after HRT in postmenopausal women p฀0.005Serum lipid
parameters, MDA, oxLDL and PON1 levels in postmenopausal women before and after HRT [74].
Similarly the effect of DNA damage by oxidative stress has been evaluated. The 8-hydroxy‐
deoxyguanosine (8-OHdG) is widely used for determination of DNA damage since it is ex‐
cised from oxidative damaged DNA with endonuclease repair enzymes coded (OGG1).
After HT, mean blood 8-OHdG (DNA damage marker) level significantly decreased com‐
pared to those before HT, while urinary 8-OHdG level did not show any difference, this
without relation with S326C polymorphism [80].
Tibolone acts as an antioxidant upon increase the concentration of reduced sulfhydryl [81],
however, the exact mechanism has not been elucidated, but it could participate in a direct
mechanism, ie through the structure tibolone and its metabolites as it is similar to the struc‐
ture of 17β-estradiol, considered as an antioxidant for its phenol ring, which can act neutral‐
izing to free radical [82, 83]. Moreover tibolone reduces the concentration of
malondialdehyde compared to those who had no treatment [84, 85].
Menopause Induces Oxidative Stress
http://dx.doi.org/10.5772/52082
303
Although there are reports that indicate the antioxidant effect of HRT, there are also studies
that indicate otherwise; in example in another study combined HRT led to decreased plasma
total and LDL cholesterol, but did not affect oxidizability and oxidation of LDL. Circulating
levels of antioxidant vitamins (beta-carotene, vitamin C, vitamin E/triglycerides) and total
antioxidant capacity of plasma and lipid peroxidation, assessed by plasma TBARs, were not
different from controls in postmenopausal women receiving HRT, which indicates that com‐
bined HRT modifies the blood lipid profile, however it does not appear to influence oxida‐
tive status [86]. Additionaly DNA damage, GPx activity and nitrite level as well as a
decreased GSH level were observed after oral administrating of estrogens alone or combi‐
nated [87].
With respect to hot flushes, they have been associated to smaller level of total antioxidant
activity in plasma, without differences in nitrite-nitrate concentrations, and after HRT there
is an increase in total antioxidant activity level and nitrite-nitrate concentrations in meno‐
pausal women, with and without hot flushes [88].
On the other side estrogen increases vasodilatation and inhibits the response of blood ves‐
sels to injury and the development of atherosclerosis, it has been related to hormone´s effect
on serum lipid concentration, that is reducing MDA and oxLDL levels and increasing activi‐
ty of paroxonase PON1, which a calcium-dependent enzyme and in serum is exclusively lo‐
cated on HDL. PON is synthesized and secreted by liver and tightly binds to HDL
subfractions that also contain apoA-1 and apoJ or clusterin and it has the capacity to protect
LDL against oxidation [89, 90, 91].
7. Effect of nutrition and exercise on oxidative stress biomarkers
Adequate nutrition and physical exercise are two factors of health promotion and its effect
on oxidative stress has been investigated in postmenopausal women, which has given con‐
troversial data. With respect to foods, they contain large amount of antioxidant molecules
from there arouse the interest to check if their use can reduce the oxidative stress observed
in postmenopause.
For example it was reported that the intake of fresh, greenhouse-grown vegetables for 3-wk
did not induced changes in the urine concentrations of 8-isoprostane F2α, hexanoyl lysine,
and serum high sensitivity C-reactive protein despite that plasma carotenoids were elevated
in overweight postmenopausal women [92]. Something similar was established with a 2-
month supplementation period with the Klamath algae extract, which is an extract naturally
rich in powerful algal antioxidant molecules (AFA-phycocyanins) and concentrated with
Klamath algae's natural neuromodulators (phenylethylamine as well as natural selective
MAO-B inhibitors), whose effect was to increase in the plasma levels of carotenoids, toco‐
pherols and retinol, however in this study oxidative stress was not measured [93, 94].
Otherwise is soy milk consumption for four weeks, which did not reduced markers of in‐
flammation and oxidative stress as (tumor necrosis factor alpha [TNF-alpha], interleukin
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[IL]-1beta, IL-6) and oxidative stress (superoxide dismutase [SOD], glutathione peroxidase
[GPx], cyclooxygenase-2 [COX-2]) [95]. In this sense has also been found that de-alcoholised
wine (DAW) with different polyphenol content by one month does not exert a protective ac‐
tivity towards oxidative DNA damage by comet assay, nor modifies significantly the gene
expression profile of peripheral lymphocytes, whereas it shows blood-fluidifying actions,
expressed as a significant decrease in blood viscosity. However, this effect does not correlate
with the dosage of polyphenols from (DAW) [96].
In contrast, the intake for 8 weeks of soya protein diet and soya nut diet decreased MDA
and increased the total antioxidant capacity in postmenopausal women with metabolic syn‐
drome [97]. Extra-virgin olive oils (EVOO) is another example of food which reduces DNA
damage by oxidative stress when is administrated for 8 weeks in healthy postmenopausal,
which was evaluated by the comet assay in peripheral blood lymphocytes [98].
Nevertheless there are also reports of foods that raise oxidative stress as with American gin‐
seng (AG) and wine. The AG supplementation at 500 mg every day for 4 months causes oxi‐
dative stress in postmenopausal women, due to reduced total antioxidant capacity, elevated
plasma malondialdehyde and urine 8-hydroxydeoxyguanosine concentrations and in‐
creased erythrocyte antioxidant enzyme activity such as erythrocyte superoxide dismutase
and GSH reductase [99].
Previous studies do not allow a conclusion on the effect of foods rich in antioxidant com‐
pounds, because were used different markers and administration time, and still more the
age range of the postmenopausal differs considerably. This shows the need for more studies.
Before shows the importance of further research with other foods with antioxidant proper‐
ties known such as:
Vitamin C - Citrus fruits and their juices, berries, dark green vegetables (spinach, asparagus,
green peppers, brussel sprouts, broccoli, watercress, other greens), red and yellow peppers,
tomatoes and tomato juice, pineapple, cantaloupe, mangos, papaya and guava.
Vitamin E - Vegetable oils such as olive, soybean, corn, cottonseed and safflower, nuts and
nut butters, seeds, whole grains, wheat, wheat germ, brown rice, oatmeal, soybeans, sweet
potatoes, legumes (beans, lentils, split peas) and dark leafy green vegetables. Selenium - Bra‐
zil nuts, brewer’s yeast, oatmeal, brown rice, chicken, eggs, dairy products, garlic, molasses,
onions, salmon, seafood, tuna, wheat germ, whole grains and most vegetables.
Beta Carotene - Variety of dark orange, red, yellow and green vegetables and fruits such as
broccoli, kale, spinach, sweet potatoes, carrots, red and yellow peppers, apricots, cantaloupe
and mangos [100].
With respect to the lycopene, the following mechanism of the role of lycopene in chronic
diseases has been mentioned by Agarwal and Rao [101] and Waliszewski and Blasco [102].
This highlights the importance of promote healthy lifestyles (balanced diet and moderate in‐
tensity exercise) in vulnerable populations, such as menopausal women, in order to prevent
aging induced oxidative stress-related diseases.
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Whit respect to the exercise has been reported that who practice yoga or tai chi (TC) for a
year have same BMI, and even more no effects were shown on erythrocyte superoxide dis‐
mutase activity, plasma lipid peroxidation (TBARS) or total homocysteine concentrations,
but the activity of erythrocyte glutathione peroxidase - an aerobic training-responsive en‐
zyme - was higher in TC practitioners [103]. Although short term aerobic physical activity
program (8 or 15 weeks) exhibited similar results, namely a reduction of serum glucose,
LDL-cholesterol (LDL-C), plasma TBARS concentrations, decreasing of HOMA(IR) as well
as an increased of total antioxidant status (TAS) of plasma and reduced glutathione (GSH)
concentrations in red blood cells (RBC) increased significantly [104, 105].
Figure 9. Lycopene and its mechanism in preventing of chronic diseases (Adapted from 101 and 102).
Regular physical training has been shown to upregulate antioxidant enzymatic systems,
which may slow down the usual increase of oxidative stress in postmenopausal women,
since it has been identified significant negative associations between oxidative stress and in‐
dices of physical fitness-activity (malondialdehyde, 8-iso-prostaglandin F2alpha, 8-hy‐
droxy-2'-deoxyguanosine). Conversely, glutathione peroxidase is positively correlated with
fitness level, furthermore mean arterial blood pressure (MABP) and cerebrovascular con‐
ductance (CVC) are directly associated with 8-hydroxy-2'-deoxyguanosine, nitrotyrosine
and nitric oxide (NO) These findings demonstrate that, after menopause, fitness level and
regular physical activity mediate against oxidative stress by maintaining antioxidant en‐
zyme efficiency. Furthermore, these results suggest that oxidative stress and NO production
modulate MABP and CVC [106].
Contrary to the above has also been reported, that the exercise does not modify the antioxi‐
dant status (although this is lower in metabolic healthy obese postmenopausal women than
non-metabolic healthy obese postmenopausal women) and worse increases serum levels of
thiobarbituric acid-reactive substances [107].
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This highlights the importance of promote healthy lifestyles (balanced diet and moderate in‐
tensity exercise) in vulnerable populations, such as menopausal women, in order to prevent
aging induced oxidative stress-related diseases.
8. Conclusion
The studies presented here were performed with different number of patients, methodolo‐
gies and biomarkers, but most of them indicate that estrogen depletion induces oxidative
stress and hormone replacement therapy seems to reduce it. With respect to the modifica‐
tion of biomarkers of oxidative stress damage by food and exercise needs more research be‐
cause so far no conclusive data have been obtained.
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